๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical experience with leucovorin and 5-fluorouracil

โœ Scribed by Leslie R. Laufman; Wayne D. Brenckman Jr; Kathy A. Stydnicki; E. D. Morgan; Mary Collier; Victoria B. Knick; David S. Duch; Robert Mullin; Robert Ferone


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
493 KB
Volume
63
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


5-fluorouracil with leucovorin in breast
โœ Charles L. Loprinzi ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 247 KB ๐Ÿ‘ 1 views

Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard fo

A comprehensive review of 5-fluorouracil
โœ David Machover ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity

Hypocalcemia associated with 5-fluoroura
โœ Yuichiro Kido; Takeshi Okamura; Morimasa Tomikawa; Manabu Yamamoto; Morio Shirai ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 367 KB ๐Ÿ‘ 2 views

## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen